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OBJECTIVES: This study sought to determine the clinical and pathological factors associated with perioperative
morbidity, mortality and oncological outcomes after multivisceral en bloc resection in patients with colorectal
cancer.
METHODS: Between January 2009 and February 2014, 105 patients with primary colorectal cancer selected for
multivisceral resection were identified from a prospective database. Clinical and pathological factors, periope-
rative morbidity and mortality and outcomes were obtained from medical records. Estimated local recurrence
and overall survival were compared using the log-rank method, and Cox regression analysis was used to
determine the independence of the studied parameters. ClinicalTrials.gov: NCT02859155.
RESULTS: The median age of the patients was 60 (range 23-86) years, 66.7% were female, 80% of tumors were
located in the rectum, 11.4% had stage-IV disease, and 54.3% received neoadjuvant chemoradiotherapy. The
organs most frequently resected were ovaries and annexes (37%). Additionally, 30.5% of patients received
abdominoperineal resection. Invasion of other organs was confirmed histologically in 53.5% of patients, and R0
resection was obtained in 72% of patients. The overall morbidity rate of patients in this study was 37.1%. Ureter
resection and intraoperative blood transfusion were independently associated with an increased number of
complications. The 30-day postoperative mortality rate was 1.9%. After 27 (range 5-57) months of follow-up,
the mortality and local recurrence rates were 23% and 15%, respectively. Positive margins were associated with
a higher recurrence rate. Positive margins, lymph node involvement, stage III/IV disease, and stage IV disease
alone were associated with lower overall survival rates. On multivariate analysis, the only factor associated with
reduced survival was lymph node involvement.
CONCLUSIONS: Multivisceral en bloc resection for primary colorectal cancer can be performed with acceptable
rates of morbidity and mortality and may lead to favorable oncological outcomes.
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’ INTRODUCTION
Approximately 12% of colorectal cancers (CRC) have
adhesions and/or tumoral infiltration into adjacent struc-
tures, requiring en bloc resection to obtain R0 resection,
which is a critical factor for increasing long-term survival (1).
Thus, treatment guidelines recommend multivisceral en bloc
resection (MVEBR) for the treatment of clinically T4b tumors,
as most studies have shown that MVEBR improves the rate
of R0 resection, which is associated with better local control
and overall survival (2,3). Neoadjuvant treatment (especially
for rectal cancers) and complete resection, including en bloc
resection of affected adjacent organs, is the standard clinical
recommendation for patients with CRC. Previous studies
have reported 5-year survival rates of 36%–53% and local
recurrence rates of less than 20% in patients with CRC (2,4,5).
In the majority of these studies, achieving an R0 resection
was the most important prognostic factor (4,5).
In the majority of cases, T4b CRC patients do not receive
MVEBR because the procedure is technically demanding andDOI: 10.6061/clinics/2017(05)01
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associated with high perioperative mortality and morbidity
when compared to standard colorectal resection (6). MVEBR
may also require interactions with other specialist areas, such
as urology, plastic surgery, vascular surgery and gynecology,
and is quite challenging even for an experienced colorectal
surgeon (4). In particular, it is often difficult to intraopera-
tively distinguish true tumoral invasion from inflammatory
adhesions. In fact, tumoral invasion into adjacent structures
is confirmed by pathological exam in approximately 50% of
cases (3,7).
MVEBR for CRC encompasses a large group of proce-
dures, ranging from simple en bloc removal of the colorectal
specimen with a small bowel loop to more complex proce-
dures, such as pelvic exenteration in association with resec-
tion of sacral bones and large pelvic vessels (3). The clinical
and pathological factors associated with morbidity and mor-
tality and oncological outcomes in CRC patients who under-
go MVEBR remain a matter of debate.
Therefore, the aim of this study was to determine the clini-
cal and pathological factors associated with perioperative
morbidity and mortality and oncological outcomes post-
MVEBR in patients with CRC.
’ METHODS
Using a prospectively collected database, patients from the
Hospital das Clínicas da Faculdade de Medicina da Universi-
dade de São Paulo - Instituto do Câncer do Estado de São
Paulo (HCFMUSP-ICESP) with primary (non-recurrent) CRC
who required MVEBR between January 2009 and February
2014 were identified and included in the present study.
Patients with potentially curative resected distant metastases
were also included. Data were obtained after approval from
the Institutional Review Board.
Preoperative work-up included colonoscopy and com-
puted tomography of the thorax and abdomen. Pelvic mag-
netic resonance imaging (MRI) was performed for adequate
locoregional staging of rectal tumors. Neoadjuvant che-
motherapy (neo CRT) was performed only in patients with
lower or mid rectal cancer and not in patients with upper
rectal or rectosigmoid junction cancer. Chemotherapy con-
sisted of an intravenous (IV) bolus of 5-FU 350 mg/m2 on
days 1 to 5 concurrent to radiation in weeks 1 and 5. The total
dose of pelvic radiation was 5,040 Gy given in 30 sessions.
Clinical and pathological characteristics included the fol-
lowing: age, gender, tumor location (colon versus rectum),
type of surgery (partial colectomy, low anterior resection or
abdominoperineal resection), use of neo CRT, number of
adjacent structures/organs excised, need for intraoperative
blood transfusion, histological differentiation (poor versus
well differentiated), margins of resection, lymph node invol-
vement, stage of disease, tumor regression grade for rectal
tumors treated with neo CRT, and pathological confirmation
of invasion of other organs or structures (pT4b).
Information about disease recurrence was obtained from
medical records, including medical notes from regular office
appointments, endoscopy, radiology, operative and pathol-
ogy reports. Patients were censored for recurrence at the time
of last follow-up. Death was confirmed through system chart
review or phone interview with the patient’s family.
Statistical Analysis
Data were described by estimated sample measures (mean,
standard deviation, median, minimum and maximum) for
quantitative variables and absolute or relative frequencies for
qualitative variables.
The association of complications, death and recurrence
with clinical and pathological characteristics in patients with-
out metastasis was assessed using chi-square, Fisher’s exact
or likelihood ratio tests. The odds ratios were estimated for
each variable of interest with each of the outcomes along with
the respective 95% confidence intervals determined from biva-
riate logistic regression.
Variables from the bivariate tests that showed a level of
significance lower than 0.20 (po0.20) were submitted to a
multiple logistic regression test, with only variables with a
significance level below 0.05 (po0.05) remaining in the final
model.
Time of death and recurrence in patients without meta-
stasis were analyzed using the Kaplan-Meier method. Log-
rank tests were performed to verify differences in survival
time.
The tests were performed with a significance level of
po0.05. Data were analyzed using SPSS 20.0 for Windows.
’ RESULTS
From January 2009 to February 2014, 1,093 patients with
CRC resections were identified at HCFMUSP/ICESP, of
which 105 (9.6%) required MVEBR and were included in
the present study. Seventy (66.7%) patients were female,
and the mean age was 60 years old (range 23-86 years). The
mean follow-up period was 27 (6.0-58.7) months. Of the
105 patients, 84 (80%) had primary rectal cancer, and 21
(20%) had primary colon cancer. Most patients had no evi-
dence of metastatic disease at diagnosis (88.6%), and 11.4%
received potentially curative resection of liver metastases.
Fifty-seven (54.3%) patients with rectal tumors received neo
CRT, as this treatment is performed only in patients with
lower or mid rectal cancer and not in those with upper rectal
and rectosigmoid junction cancers.
All procedures were performed via laparotomy. Low ante-
rior resection was performed in 62% of cases, abdomino-
perineal resection in 30.5%, and partial colectomy in 7.5%.
Twelve patients had their perineal defect closed by gluteal-
fold flaps. Fifty-three patients (50.4%) had only one adjacent
organ excised en bloc with the colorectal specimen, and 52
patients (49.6%) required excision of two or more adjacent
organs. The organs most frequently excised were the ovaries
and annexes (37%), followed by the uterus (30%), vagina
(26%), bladder (21%), and prostate (13%). The sacrum, small
bowel, ureter and other organs were also excised in a few
cases. True invasion of adjacent organs was confirmed by
way of pathologic assessment in 53.5% of surgical specimens.
Free margins were obtained in 81.9% of patients, while com-
plete pathologic response (ypT0N0) was observed in 4.5% of
rectal tumors.
Overall, the morbidity rate was 37.1%. Wound infection
was the most frequent complication (16.2%), followed by
paralytic ileus (8.5%), urinary fistulae (3.8%), intra-abdom-
inal abscess (2.8%), anastomotic leak (1.9%), abdominal wall
dehiscence (partial or complete) (1.5%), enteric fistula (1%),
and external iliac artery lesion (1%). Ten percent of patients
developed significant complications that required surgi-
cal intervention. Thirty-two percent of patients received an
intraoperative blood transfusion (median 1.7 units, range
1-6). The median length of hospital stay was 11 (range 6-25)
days.
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Table 1 shows the analysis of potential factors related
to complications and the likelihood of these associations.
Patients who underwent resection of the ureter or required
intraoperative blood transfusion were significantly more
likely to suffer a complication (p=0.018 and po0.001, respec-
tively). The multiple logistic regression model confirmed that
ureter resection and intraoperative blood transfusion were
independently associated with a 5.6- and 7.3-fold increased
risk of complications, respectively.
The 30-day postoperative mortality rate of 1.9% (2 patients)
was not associated with any of the studied parameters. After
a mean follow-up period of 27 (range 5-57) months, the
overall mortality rate was 23%, and the local recurrence
rate was 15%. In non-metastatic patients, a positive margin
was the only factor associated with a higher recurrence rate
(p=0.002).
The Kaplan-Meier curve showed that the estimated 5-year
overall survival rate was 47.5%. In univariate analysis,
Table 1 - Description of complications according to the studied variables and tests of association.
Complication
Variable No (N = 66) Yes (N = 39) OR Total (N = 105) p
N % n %
Gender 40.999
Female 44 62.9 26 37.1 1.00 70
Male 22 62.9 13 37.1 1.00 35
Primary tumor 0.106
Rectum 56 66.7 28 33.3 1.00 84
Colon 10 47.6 11 52.4 2.20 21
Type of surgery 0.926#
APR 21 65.6 11 34.4 1.00 32
Low anterior resection 40 61.5 25 38.5 1.19 65
Colectomy 5 62.5 3 37.5 1.15 8
Gluteal flap** 0.465*
No 12 60 8 40 1.00 20
Yes 9 75 3 25 0.50 12
Bladder 0.100
No 52 67.5 25 32.5 1.00 77
Yes 14 50 14 50 2.08 28
Uterus 0.071
No 50 68.5 23 31.5 1.00 73
Yes 16 50 16 50 2.17 32
Vagina 0.784
No 49 63.6 28 36.4 1.00 77
Yes 17 60.7 11 39.3 1.13 28
Ovaries and annexes 0.168
No 46 67.6 22 32.4 1.00 68
Yes 20 54.1 17 45.9 1.78 37
Small bowel 40.999*
No 58 62.4 35 37.6 1.00 93
Yes 8 66.7 4 33.3 0.83 12
Ureter 0.018*
No 63 67.0 31 33.0 1.00 94
Yes 3 27.3 8 72.7 5.42 11
Prostate 40.999*
No 58 63.0 34 37.0 1.00 92
Yes 8 61.5 5 38.5 1.07 13
Seminal vesicle 0.758*
No 59 63.4 34 36.6 1.00 93
Yes 7 58.3 5 41.7 1.24 12
Sacrum 0.293*
No 63 61.8 39 38.2 1.00 102
Yes 3 100.0 0 0 3
Number of organs resected 0.058
1 38 71.7 15 28.3 1.00 53
X2 28 53.8 24 46.2 2.17 52
Tumor differentiation 0.364
Poor 11 73.3 4 26.7 1.00 15
Well/moderate 55 61.1 35 38.9 1.75 90
Blood transfusion o0.001
No 55 77.5 16 22.5 1.00 71
Yes 11 32.4 23 67.6 7.19 34
Neo CRT 0.199
No 27 56.2 21 43.8 1.00 48
Yes 39 68.4 18 31.6 0.59 57
Result of the chi-square test; * Result of Fisher’s exact test; # Result of the likelihood ratio test; & Is not predictable; **
Neo CRT = Neoadjuvant chemotherapy
APR = Abdominoperineal resection.
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positive margins, lymph node involvement, stage III/IV
disease, and stage IV disease alone were associated with
lower overall survival, as presented in Table 2. The Cox mul-
tiple regression model showed that the presence of lymph
node involvement was the only independent risk factor for
poor survival.
The estimated 5-year survival rate for patients without
metastatic disease was 58.7%, while that for patients with
metastatic diseases was 15%. The estimated 5-year survival
rates for patients with and without R0 resection were 61.1%
and 24.1%, respectively. Finally, the estimated 5-year survival
rates for patients with and without lymph node involvement
were 32.8% and 59.8%, respectively (Figure 1).
’ DISCUSSION
MVEBR for clinically non-recurrent T4b CRC constitutes a
demanding group of procedures. However, a multidisciplin-
ary approach can offer favorable oncological outcomes with
an acceptable morbidity and mortality rate, as demonstrated
in our study.
Direct comparison of our results to those of other studies
is difficult due to the wide variation in inclusion criteria
(colonic, rectal or both types of tumors), as well as the inclu-
sion of primary and recurrent cancers. In this study, we
included only primary advanced CRC patients requiring a
multivisceral resection procedure.
In a systematic review of 1,575 patients, 87% of MVEBR
cases were performed for non-recurrent CRC, and 64% of the
cases had tumors in the rectum (8). In our study, all our cases
were non-recurrent with a high proportion of rectal cancer,
which is more prone to local invasion of organs and struc-
tures in proximity of the tumor.
Reviewing the English-language literature indexed on
PubMed between 2008 and 2015, we identified 6 other case
series containing a minimum of 40 cases of non-recurrent
CRC, as shown in Table 3. Our series represents the second
largest number of patients (range of patients included in
studies: 42-124). Metastatic patients were present in fewer
than 20% of these series. The overall morbidity rate in this
study was 37.1%, which is concordant with the results of
other series (range 24-50%) (3,9-13). However, it is important
to state that only 10% of patients in this study required
surgical or image-guided intervention for these complica-
tions. Treatment with a multidisciplinary team likely con-
tributed to the positive clinical outcomes in this sample.
The use of radiological images (e.g., pelvic MRI images)
led to better preparation for surgery and allowed for the
organization of a multidisciplinary surgical team to select
patients suited to this type of surgery, to plan intraoperative
strategies, and to predict difficulties in the postoperative
period.
A higher rate of morbidity would be expected in male
patients as a result of anatomical characteristics, such as a
typically narrower pelvis. However, the two series with pre-
dominantly male patients reported morbidity rates of 24%
and 50% (3,10). These results were not significantly different
from those of studies not composed predominantly of male
Table 2 - Description of overall survival according to the studied variables.
Variable Mean time estimate Std. error (mean) 95% CI HR 95% CI (HR) Death by cancer Total N % p
Margins 0.027
Negative 42.6 3.3 36.1-49.0 1.00 1.0-5.1 18 86 20.9
Positive 25.1 4.8 15.7-34.6 2.35 10 17 58.8
N+ 0.019
No 40.6 3.2 34.3-46.9 1.00 1.1-5.0 12 65 18.5
Yes 30.5 4.7 21.2-39.8 2.39 16 38 42.1
pT4 0.129
No 39.6 3.5 32.7-46.5 1.00 0.8-4.1 9 40 22.5
Yes 34.5 4.1 26.5-42.6 1.84 19 63 30.2
Tumor differentiation 0.252
Poor 29.5 5.4 18.8-40.2 1.00 0.2-1.5 5 14 35.7
Well or moderate 39.2 3.2 33.0-45.5 0.57 23 89 25.8
Blood transfusion 0.112
No 44.2 3.5 37.4-51.1 1.00 0.8-3.8 14 71 19.7
Yes 31.0 4.1 23.0-39.1 1.82 14 32 43.8
Final stage 0.023
0/I/II 40.3 3.3 33.9-46.8 1.00 1.1-4.9 12 65 18.5
III/IV 31.2 4.6 22.1-40.3 2.34 16 38 42.1
Primary tumor 0.850
Rectum 35.6 2.7 30.3-41.0 1.00 0.3-2.4 23 83 27.7
Colon 36.5 7.5 21.9-51.2 0.91 5 20 25.0
Type of surgery 0.821
APR 33.3 3.6 26.3-40.4 1.00 10 31 32.3
Low anterior resection 39.1 3.8 31.6-46.5 0.78 0.3-1.7 17 64 26.6
Colectomy 14.5 1.9 10.6-18.4 0.76 0.1-6.0 1 8 12.5
Neo CRT 0.209
No 33.5 4.4 24.8-42.2 1.00 0.3-1.3 16 46 34.8
Yes 37.9 2.5 32.9-42.9 0.62 12 57 21.1
Distant metastases 0.018
No 42.5 3.1 36.3-48.7 1.00 1.1-6.0 20 91 22.0
Yes 23.1 4.3 14.6-31.7 2.63 8 12 66.7
Total 38.6 3.0 32.7-44.5 28 103 27.2
Result of the chi-square test; * Result of Fisher’s exact test; #
Neo CRT = Neoadjuvant chemotherapy p: Pathological status N+: Nodal disease
APR = Abdominoperineal resection.
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patients, such as the current study (morbidity ranged from
25-48%) (9,11-13).
Morbidity was higher in cases of tumors located in the
rectum and was similar to other studies (39-50%) (3,12,13).
Rectal surgery is generally more difficult (especially in nar-
row pelvises with bulky tumors, and tumors in close pro-
ximity to nerves, vessels, and urinary and sexual organs) and
carries a greater risk of temporary or definitive stoma. In
addition, higher morbidity could also be expected due to the
frequent use of neo CRT in rectal tumors.
We did not observe any notable difference in terms of peri-
operative 30-day mortality between the series (rates varied
from 0% to 4%) (3-6). However, this result could not be con-
clusively demonstrated due to the small sample size.
In the present series, perioperative blood transfusions
were associated with a higher frequency of postoperative
morbidity, with 7.2 times the overall rate of complications.
Few series in the literature have reported the need for blood
transfusion, and those that have did not evaluate the
correlation with complications. In others studies, 68% of
patients required blood transfusions in advanced colonic
cancer (10), and 40% of rectal cancer patients required
perioperative transfusions (14). Blood transfusion likely
reflects the severity of the illness and the more involved
nature of the surgery, rather than constituting a risk factor
by itself.
Length of stay after a major resection could possibly
influence perioperative morbidity. The duration of post-
operative hospital stay in the present study was 11 (range
6-25) days. A series of 42 MVEBR procedures for rectal
cancer reported that patients stayed a mean of 16 days,
which is longer than that reported in this series (3). However,
this information was not routinely reported in the other
studies (5,9).
In this study, invasion of other organs was confirmed by
pathological examination in 53.5% of the samples, which
was similar to the majority of the other series (range 34 to
58%) (11). Peritumoral inflammation may result in adhesions
that are indistinguishable from true malignant invasion of
proximal organs and structures during the surgical proce-
dure. Surgeons must always try to perform en bloc resection,
including any adherent structures, to achieve R0 resection
(15-17). The organs most frequently resected in this study
were the ovaries and annexes, followed by the uterus,
vagina, bladder, and prostate. Likewise, in the other series
that included solely rectal cancer patients, gynecological
organs were the organs most frequently resected (10,12,13).
The bladder was the most commonly resected organ in some
Figure 1 - Kaplan-Meier overall survival curves for patients with and without lymph node involvement. (p=0.019).
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papers, (3) while the small bowel was the most frequently
resected in others (9,11). This difference is likely because
these two latter series included 66% of patients with colon
cancer. In addition, two or more organs were excised in 43%
of the procedures in the present study, and this was not sig-
nificantly associated with complications despite a tendency
for this occurrence (p=0.058).
Free margins were obtained in 72% of our patients, which
is in line with other results in the literature (range 72%-91%)
(3,9-13). An R0 resection was identified as a positive prog-
nostic factor in several studies (18-20), while a meta-analysis
and single-center study demonstrated significantly redu-
ced overall survival rates for patients in whom a transection
of the tumor from adhesive structures was attempted (5,8).
In the present series, positive margins increased the recur-
rence rate and reduced the overall survival rate, which could
mean that R0 resection and accurate surgery without
excessive tumor manipulation constitute optimal treatment
for these patients. A non-R0 resection was also associated
with poor prognosis and local recurrence (12) and was
associated with poor prognoses in the other four series as
well (9,11-13).
Complete pathological response was observed in 4.5% of
rectal tumors after neo CRT in this study, similar to the rate
of 4.7% reported (3) for rectal tumors in other studies. Asses-
sing the role of neo CRT in cases of complete pathological
response was limited by the heterogeneity of studies and
the small numbers of included patients. However, patients
with a complete pathological response underwent MVEBR,
which shows that clinical, radiological and even surgical
assessment of the tumor response after neo CRT still has
major limitations.
The estimated 5-year overall survival rate of 47.5% is in
line with other studies (range 49-69%). In a systematic
review, the weighted mean overall 5-year survival rate was
50.3% (8). We would like to emphasize that a 61% survival
rate was estimated in patients with R0 resection, comparable
to the 64% rate reported by Campos et al. (9). A lower rate of
48% was reported (3) for R0 resection patients.
In this study, lymph node involvement was significantly
and independently associated with a decreased survival rate.
This association was also observed in another study (13).
However, reasonable 5-year survival rates could be achieved
with MVEBR even in patients with nodal disease (13,21-24).
Other reported poor prognostic factors for survival inclu-
ded rectal tumor location (9), adverse histological features
(9), presence of distant metastasis (3,12), palliative surgery
(8,25), and non-sphincter preserving procedures (12).
There are some limitations of this study that need to be
acknowledged, including the retrospective collection of data
and a short follow-up period.
Ureter resection and intraoperative blood transfusion were
associated with higher rates of early postoperative complica-
tions. Lymph node involvement was associated with poor
overall survival, and positive margins were associated with
recurrence in non-metastatic patients.
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Table 3 - Summary of the English-language literaturein PubMed regarding multivisceral resection performed in patients with
non-recurrent CRC from 2008-2015.
Present study Campos 2008 Genzen 2012 Harris 2010 Hoffmann 2012 Smith 2012 Derici 2008
Number of
patients
105 90 90 42 78 124 57
Gender M:F 33%:67% 39%:61% 65%:35% 74%:26% 48%:52% 27%:73% 33%:67%
Distant
metastases
11% 15% 12% 12% 0% 20% 0%
*R0 72% 84.4%% 91% 79% 82% 84.6% 75.4%
True invasion 53.5% 57.8% 34.4% 52.3% 48.7% 43% 58%
N+ 38% 58% 40% 47.7% 63% 25.8% 61%
Tumor site 80% rectal 66% colon 57% colon 100% rectal 66.7% colon 100% rectal 100% rectal
Organs involved Annexes: 37%
Uterus: 30%
Vagina: 26%
Bowel: 19.8%
Bladder: 16.4%
Uterus: 12.9%
Ovary: 26.6%
Bladder: 25.5%
Bowel: 21%
Bladder: 54.7%
Uterus/
Annexes: 26.1%
Bowel: 17%
Bladder: 10%
Ovary: 9.4%
Vagina: 51%
Uterus: 23%
Bladder: 10%
Annexes: 47%
Uterus: 32%
Bladder: 30%
Morbidity 37.1% 25% 24.4% 50% 34.6% 47.6% 39%
Mortality (30 d) 1.9% 3% 4.2% 0% 7.7% 0.8% 3.5%
Overall mortality 23% 28% NA NA NA NA 47%
Local recurrence 20% 34% 12% 7% 5% 18.8% 18.2%
5-year survival Overall: 47.5%
R0: 61%
Non-R0: 24%
M1: 15%
R0: 64%
R1,R2: 0%
Overall 69% R0: 48%
R1,R2: 33%
M1: 0%
Overall 55% Overall 53% Overall 49%
Poor prognostic
factors for local
recurrence
Resection
margins
Tumor location NR Metastatic and
nodal disease
NR Resection
margins
Adjuvant
treatment
Poor prognostic
factors for
survival
Nodal disease Tumor location NR Nodal disease Resection
margins
Resection
margins and
distant
metastases
Nodal disease
and resection
margins
NR: Not reported.
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